<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00042783</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069468</org_study_id>
    <secondary_id>SWOG-S0116</secondary_id>
    <nct_id>NCT00042783</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Stage IV Melanoma</brief_title>
  <official_title>A Phase II Trial Of A D1/3-MAGE3-HIS Fusion Protein (NSC-719274) With Adjuvant SBAS02B (NSC-719275) For Patients With Stage IV, M1a or M1b Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Vaccine&#xD;
      therapy may be effective in treating stage IV melanoma.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients&#xD;
      who have stage IV melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility of treating patients with stage IV melanoma with&#xD;
           D1/3-MAGE-3-His fusion protein with SB-AS02B adjuvant.&#xD;
&#xD;
        -  Determine the clinically confirmed response rates (partial and complete responses) of&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the 6-month progression-free survival rate of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the qualitative and quantitative toxic effects of this regimen in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine immune responses in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive D1/3-MAGE-3-His fusion protein emulsified in SB-AS02B adjuvant&#xD;
      intramuscularly once every 3 weeks for a total of 12 weeks (4 injections). In the absence of&#xD;
      disease progression or unacceptable toxicity, patients receive a second 12-week course&#xD;
      beginning at week 16.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year and then every 6 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 25-45 patients will be accrued for this study within 5-9&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>D1/3-MAGE-3-His fusion protein</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB-AS02B adjuvant</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage IV melanoma that is considered incurable by surgery,&#xD;
             radiotherapy, or limb perfusion&#xD;
&#xD;
               -  M1a or M1b disease&#xD;
&#xD;
          -  Measurable disease outside prior field of limb perfusion&#xD;
&#xD;
          -  Metastatic mucosal melanoma allowed&#xD;
&#xD;
          -  MAGE-3 positive by reverse transcription polymerase chain reaction&#xD;
&#xD;
          -  No uveal or choroidal primary melanoma&#xD;
&#xD;
          -  No prior or concurrent brain metastases by CT scan or MRI of the brain&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Zubrod 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C negative&#xD;
&#xD;
          -  No liver cirrhosis&#xD;
&#xD;
          -  No unstable liver disease&#xD;
&#xD;
          -  No coagulation disorders&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No major cardiovascular illness&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No major pulmonary illness&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No AIDS or HIV-1-associated complex&#xD;
&#xD;
          -  No chronic alcohol abuse or drug addiction&#xD;
&#xD;
          -  No systemic infections&#xD;
&#xD;
          -  No prior active autoimmune disease&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated&#xD;
             stage I or II cancer from which the patient is currently disease-free&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 4 weeks since prior adjuvant biologic therapy&#xD;
&#xD;
          -  No prior biologic therapy for stage IV melanoma&#xD;
&#xD;
          -  No prior MAGE-3 peptide or protein vaccine preparation&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior adjuvant chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for stage IV melanoma&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior adjuvant radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 4 weeks since prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior limb perfusion and recovered&#xD;
&#xD;
          -  At least 4 weeks since other prior adjuvant therapy&#xD;
&#xD;
          -  No other prior therapy for stage IV melanoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey S. Weber, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Cancer Center at University of Arizona Health Sciences Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center and Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Biloxi</name>
      <address>
        <city>Biloxi</city>
        <state>Mississippi</state>
        <zip>39531-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Columbia River Oncology Program</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington School of Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-6527</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2004</verification_date>
  <study_first_submitted>August 5, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 21, 2013</last_update_submitted>
  <last_update_submitted_qc>June 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

